Mariacristina Siotto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7581739/publications.pdf

Version: 2024-02-01

257101 264894 59 1,823 24 42 citations g-index h-index papers 60 60 60 2352 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Oxidative Stress Status in Post Stroke Patients: Sex Differences. Healthcare (Switzerland), 2022, 10, 869.	1.0	8
2	Pet Presence Can Reduce Anxiety in the Elderly: The Italian Experience during COVID-19 Lockdown Assessed by an Electronic Survey. International Journal of Environmental Research and Public Health, 2022, 19, 6135.	1.2	4
3	Effects of Social Distancing on Quality of Life and Emotional-Affective Sphere of Caregivers and Older Patients Hospitalized in Rehabilitation Departments during COVID-19 Quarantine: An Observational Study. Diagnostics, 2022, 12, 1299.	1.3	1
4	A Remote Assessment of Anxiety on Young People: Towards Their Views and Their Different Pet Interaction. Healthcare (Switzerland), 2022, 10, 1242.	1.0	0
5	Association Study of SLC6A4 (5-HTTLPR) Polymorphism and Its Promoter Methylation with Rehabilitation Outcome in Patients with Subacute Stroke. Genes, 2021, 12, 579.	1.0	5
6	Serotonin Levels and Cognitive Recovery in Patients with Subacute Stroke after Rehabilitation Treatment. Brain Sciences, $2021,11,642.$	1.1	8
7	BDNF rs6265 Polymorphism and Its Methylation in Patients with Stroke Undergoing Rehabilitation. International Journal of Molecular Sciences, 2020, 21, 8438.	1.8	10
8	Total Serum Calcium and Recovery after Rehabilitation in Patients with Stroke. Applied Sciences (Switzerland), 2020, 10, 7893.	1.3	2
9	Vitamin D and Rehabilitation after Stroke: Status of Art. Applied Sciences (Switzerland), 2020, 10, 1973.	1.3	6
10	Single nucleotide polymorphisms in the human <i>ATP7B</i> gene modify the properties of the ATP7B protein. Metallomics, 2019, 11, 1128-1139.	1.0	15
11	Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability. Frontiers in Neuroscience, 2019, 13, 86.	1.4	40
12	Copper in Glucose Intolerance, Cognitive Decline, and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 77-85.	0.6	15
13	ATP7B and Alzheimer Disease. , 2019, , 427-436.		1
14	Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers. Journal of Alzheimer's Disease, 2018, 62, 1507-1518.	1.2	18
15	20 Value of Serum Oxidative Stress and Metal Profiling for Post-Stroke Functional Recovery. American Journal of Clinical Pathology, 2018, 149, S8-S9.	0.4	0
16	26 Copper Failure in Wilson and Alzheimer Disease. American Journal of Clinical Pathology, 2018, 149, S11-S11.	0.4	0
17	Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators. Journal of Trace Elements in Medicine and Biology, 2018, 45, 181-188.	1.5	7 3
18	Excess Copper in Alzheimer Disease but Not in Frontotemporal Lobar Degeneration: Next-Generation Sequencing Study of ATP7B Gene in Patients Typified by High Copper. American Journal of Clinical Pathology, 2018, 150, S65-S66.	0.4	0

#	Article	IF	Citations
19	Copper Abnormalities in Psychiatric Disorders: Searching for ATP7B Mutations. American Journal of Clinical Pathology, 2018, 150, S67-S67.	0.4	O
20	Copper and Zinc Dysregulation in Alzheimer's Disease. Trends in Pharmacological Sciences, 2018, 39, 1049-1063.	4.0	188
21	Prognostic Value of Serum Copper for Post-Stroke Clinical Recovery: A Pilot Study. Frontiers in Neurology, 2018, 9, 333.	1.1	12
22	Copper imbalance in Alzheimer's disease: Overview of the exchangeable copper component in plasma and the intriguing role albumin plays. Coordination Chemistry Reviews, 2018, 371, 86-95.	9.5	44
23	Serum Copper is not Altered in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 63, 1427-1432.	1.2	6
24	Measurements of serum non-ceruloplasmin copper by a direct fluorescent method specific to Cu(II). Clinical Chemistry and Laboratory Medicine, 2017, 55, 1360-1367.	1.4	33
25	An exploratory study of BDNF and oxidative stress marker alterations in subacute and chronic stroke patients affected by neuropathic pain. Journal of Neural Transmission, 2017, 124, 1557-1566.	1.4	13
26	Copper in Alzheimer's Disease. , 2017, , 19-34.		1
27	Commentary: The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease. Frontiers in Neurology, 2017, 8, 503.	1.1	22
28	Role of Copper in the Onset of Alzheimer's Disease Compared to Other Metals. Frontiers in Aging Neuroscience, 2017, 9, 446.	1.7	141
29	Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study. Current Alzheimer Research, 2017, 14, 1318-1326.	0.7	22
30	Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 1181-1189.	1.2	51
31	Non-ceruloplasmin bound copper and ATP7B gene variants in Alzheimer's disease. Metallomics, 2016, 8, 863-873.	1.0	39
32	Association between sex, systemic iron variation and probability of Parkinson's disease. International Journal of Neuroscience, 2016, 126, 354-360.	0.8	19
33	Non-Ceruloplasmin Copper Distinguishes A Distinct Subtype of Alzheimer's Disease: A Study of EEG-Derived Brain Activity. Current Alzheimer Research, 2016, 13, 1374-1384.	0.7	24
34	Metals Involvement in Alzheimer's Disease — A Patho-Genetic View. , 2015, , .		1
35	Meta-Analysis Study on the Role of Bone-Derived Neurotrophic Factor Val66Met Polymorphism in Parkinson's Disease. Rejuvenation Research, 2015, 18, 40-47.	0.9	11
36	Movement disorders and brain iron overload in a new subtype of aceruloplasminemia. Parkinsonism and Related Disorders, 2015, 21, 658-660.	1.1	10

#	Article	IF	CITATIONS
37	Zinc in Alzheimer's Disease: AÂMeta-Analysis of Serum, Plasma, andÂCerebrospinal Fluid Studies. Journal of Alzheimer's Disease, 2015, 46, 75-87.	1.2	75
38	Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy. Metabolic Brain Disease, 2015, 30, 1445-1452.	1.4	11
39	Towards a Unified Vision of Copper Involvement in Alzheimer's Disease: A Review Connecting Basic, Experimental, and Clinical Research. Journal of Alzheimer's Disease, 2015, 44, 343-354.	1.2	64
40	Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. Annals of Neurology, 2014, 75, 574-580.	2.8	93
41	Low-copper diet as a preventive strategy for Alzheimer's disease. Neurobiology of Aging, 2014, 35, S40-S50.	1.5	81
42	Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy. Journal of Neural Transmission, 2014, 121, 1281-1286.	1.4	34
43	In silico investigation of the ATP7B gene: insights from functional prediction of non-synonymous substitution to protein structure. BioMetals, 2014, 27, 53-64.	1.8	21
44	ATP7B Variants as Modulators of Copper Dyshomeostasis in Alzheimer's Disease. NeuroMolecular Medicine, 2013, 15, 515-522.	1.8	60
45	A comparison between radiometric and fluorimetric methods for measuring SSAO activity. Journal of Neural Transmission, 2013, 120, 1015-1018.	1.4	5
46	Inflammation and iron metabolism in adult patients with epilepsy: Does a link exist?. Epilepsy Research, 2013, 107, 244-252.	0.8	32
47	Meta-Analysis of Serum Non-Ceruloplasmin Copper in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 809-822.	1.2	101
48	Antioxidant Status and APOE Genotype As Susceptibility Factors for Neurodegeneration in Alzheimer's Disease and Vascular Dementia. Rejuvenation Research, 2013, 16, 51-56.	0.9	17
49	Levels of Serum Ceruloplasmin Associate With Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 370-375.	0.9	45
50	Intronic rs2147363 Variant in ATP7B Transcription Factor-Binding Site Associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 453-459.	1.2	24
51	Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. Frontiers in Aging Neuroscience, 2013, 5, 37.	1.7	30
52	Metal Dysfunction in Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 73-97.	0.4	3
53	Metal-Score as a Potential Non-Invasive Diagnostic Test for Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 191-198.	0.7	28
54	582 METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY. Journal of Hepatology, 2012, 56, S231.	1.8	0

#	Article	IF	CITATIONS
55	Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1633-1641.	1.5	57
56	Ceruloplasmin/Transferrin Ratio Changes in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	35
57	Copper in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies. Journal of Alzheimer's Disease, 2011, 24, 175-185.	1.2	109
58	Copper Status Abnormalities and How to Measure Them in Neurodegenerative Disorders. Recent Patents on CNS Drug Discovery, 2010, 5, 182-194.	0.9	13
59	Structural Determinants ofTorpedocalifornicaAcetylcholinesterase Inhibition by the Novel and Orally Active Carbamate Based Anti-Alzheimer Drug Ganstigmine (CHF-2819)â€. Journal of Medicinal Chemistry, 2006, 49, 5051-5058.	2.9	42